{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:37Z","timestamp":1792545637423,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["UL1TR004419"],"award-info":[{"award-number":["UL1TR004419"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00966-7","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:02:51Z","timestamp":1746766971000},"page":"988-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial"],"prefix":"10.1038","volume":"6","author":[{"given":"Mansi","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kodysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Kaminska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Meseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hapanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot Anthony","family":"Niglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rubinsteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-2426","authenticated-orcid":false,"given":"Robert P.","family":"Sebra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-4187","authenticated-orcid":false,"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"966_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"966_CR2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547\u20131557 (2020).","journal-title":"Lancet"},{"key":"966_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"966_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"966_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"966_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"966_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for melanoma patients. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"966_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"966_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"966_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577\u2013581 (2014).","journal-title":"Nature"},{"key":"966_CR13","doi-asserted-by":"publisher","first-page":"LB048","DOI":"10.1158\/1538-7445.AM2021-LB048","volume":"81","author":"TU Marron","year":"2021","unstructured":"Marron, T. U. et al. Abstract LB048: an adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Cancer Res. 81, LB048 (2021).","journal-title":"Cancer Res."},{"key":"966_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"966_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"966_CR16","doi-asserted-by":"publisher","first-page":"e007613","DOI":"10.1136\/jitc-2023-007613","volume":"11","author":"J Anker","year":"2023","unstructured":"Anker, J. et al. Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer. J. Immunother. Cancer 11, e007613 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"966_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0934","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematological malignancies in the adjuvant setting. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0934 (2025).","journal-title":"Cancer Discov."},{"key":"966_CR18","doi-asserted-by":"crossref","unstructured":"Kodysh, J. & Rubinsteyn, A. OpenVax: an open-source computational pipeline for cancer neoantigen prediction. in Bioinformatics for Cancer Immunotherapy: Methods and Protocols (ed. Boegel, S.) 147\u2013160 (Springer, 2020).","DOI":"10.1007\/978-1-0716-0327-7_10"},{"key":"966_CR19","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","volume":"24","author":"C Kyi","year":"2018","unstructured":"Kyi, C. et al. Therapeutic immune modulation against solid cancers with intratumoral Poly-ICLC: a pilot trial. Clinical Cancer Res. 24, 4937\u20134948 (2018).","journal-title":"Clinical Cancer Res."},{"key":"966_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556 (2017).","journal-title":"Cell"},{"key":"966_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"966_CR22","doi-asserted-by":"publisher","first-page":"e008817","DOI":"10.1136\/jitc-2024-008817","volume":"12","author":"SK M\u00f8rk","year":"2024","unstructured":"M\u00f8rk, S. K. et al. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. J. Immunother. Cancer 12, e008817 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"966_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51315-8","volume":"15","author":"P Latzer","year":"2024","unstructured":"Latzer, P. et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat. Commun. 15, 6870 (2024).","journal-title":"Nat. Commun."},{"key":"966_CR24","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen, X., Yang, J., Wang, L. & Liu, B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 10, 6011\u20136023 (2020).","journal-title":"Theranostics"},{"key":"966_CR25","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"966_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","volume":"8","author":"A Pavlick","year":"2020","unstructured":"Pavlick, A. et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol. Res. 8, 70\u201380 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"966_CR27","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res."},{"key":"966_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"966_CR29","doi-asserted-by":"publisher","first-page":"LBA443","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA443","volume":"41","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Extended follow-up results from the CheckMate 274 trial. J. Clin. Oncol. 41, LBA443 (2023).","journal-title":"J. Clin. Oncol."},{"key":"966_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur. Urol. 76, 599\u2013603 (2019).","journal-title":"Eur. Urol."},{"key":"966_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3389\/fimmu.2017.01807","volume":"8","author":"A Rubinsteyn","year":"2017","unstructured":"Rubinsteyn, A. et al. Computational pipeline for the PGV-001 neoantigen vaccine trial. Front. Immunol. 8, 1807 (2017).","journal-title":"Front. Immunol."},{"key":"966_CR32","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","volume":"183","author":"V Roudko","year":"2020","unstructured":"Roudko, V. et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183, 1634\u20131649 (2020).","journal-title":"Cell"},{"key":"966_CR33","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.xpro.2021.100758","volume":"2","author":"C Cimen Bozkus","year":"2021","unstructured":"Cimen Bozkus, C., Blazquez, A. B., Enokida, T. & Bhardwaj, N. A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses. STAR Protoc. 2, 100758 (2021).","journal-title":"STAR Protoc."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00966-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:31:54Z","timestamp":1750915914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00966-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00966-7","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.S. is the chairman, CEO, scientific director and cofounder of Oncovir. R.P.S. is a paid consultant and equity holder at GeneDx and is the CEO and founder of Panacent Bio. N.B. has served as an advisor or board member for Carisma Therapeutics, CureVac, Genotwin, DC Prime, Rome Therapeutics and Tempest Therapeutics, has stock options in Genotwin, DC Prime and Vaccitech, has served as a consultant for Merck Research Laboratories, has received research support from Harbour Biomed Sciences and is an extramural member of the Parker Institute for Cancer Immunotherapy. M.D.G. has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech and has served as a consultant to Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie and Analog Devices. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}